Anebulo Pharmaceuticals(US:ANEB)2026-02-12 21:30Product Development - The company is developing selonabant, a cannabinoid receptor antagonist, to address cannabis-induced toxicity, with both oral and intravenous formulations anticipated to reverse symptoms effectively [71]. - The Netherlands Trial for oral selonabant involved 134 subjects and completed in August 2023, with positive results supporting further development [74]. - The FDA indicated that a well-controlled study of oral selonabant in ACI patients could provide substantial evidence for a new drug application [74]. - The company is prioritizing the intravenous formulation of selonabant for pediatric patients, aiming for a faster approval timeline compared to the adult oral product [75]. - A cooperative grant of approximately $1.9 million from NIDA was awarded to support the development of intravenous selonabant for pediatric cannabis toxicity [83]. - The company initiated a single ascending dose study of IV selonabant in healthy adults in Q3 2025, with ongoing observational studies focusing on pediatric patients [75]. Financial Performance - The company has not generated any revenue since inception and expects to continue incurring significant operating losses and negative cash flows from operations in the future [88]. - Research and development expenses for the three months ended December 31, 2025, were $1,164,737, a decrease of $55,798 compared to the same period in 2024 [93]. - General and administrative expenses for the three months ended December 31, 2025, were $1,455,173, an increase of $87,557 compared to the same period in 2024 [100]. - The company reported a net cash used in operating activities of approximately $2.6 million for the six months ended December 31, 2025, compared to $3.1 million for the same period in 2024 [109][110]. - The company has a net loss of $4.2 million for the six months ended December 31, 2025, partially offset by non-cash stock-based compensation and loan commitment amortization [109]. Cash and Funding - The company had cash and cash equivalents of approximately $9.0 million as of December 31, 2025, which is expected to fund operations for at least the next 12 months [105]. - The company expects its cash and cash equivalents, along with access to the Loan Agreement, to fund operations for at least the next 12 months [111]. - The company received aggregate gross proceeds of approximately $15.0 million from a private placement in December 2024 [110]. - The outstanding balance of the Loan Agreement will accrue interest at 0.25% per annum, with a maximum loan advance reduced to $3 million [107]. - The company is required to issue 0.03 shares of common stock per dollar loaned under the Loan Agreement, up to a maximum of 90,000 shares [107]. - The company anticipates needing additional equity or debt financing to support its operations and product development in the future [114]. Stock and Corporate Actions - A proposed reverse stock split of not less than 1-for-2,500 and not greater than 1-for-7,500 is part of a plan to go private and reduce the number of record holders below 300 [85]. - The company plans to voluntarily delist its Common Stock from Nasdaq and deregister with the SEC, aiming to maintain the number of stockholders below 300 [87]. - The company announced a tender offer to purchase up to 300,000 shares of Common Stock at a price of $3.50 per share, resulting in an aggregate cost of approximately $1.05 million [86]. - The tender offer was oversubscribed, with a total of 4,907,881 shares tendered, and the final proration factor was 3.47392% [86]. Research and Development Agreements - The company has a manufacturing agreement with a third-party CMO costing approximately $3.0 million, expected to be substantially completed by June 30, 2024 [118]. - The company entered into a contract with a third-party CRO for a Phase 1 SAD study, with a total cost of approximately $3.5 million, expected to be completed by the third quarter of calendar 2026 [119]. - The company has potential developmental milestone payments of up to $29.9 million related to the License Agreement with Vernalis, of which $0.4 million has been paid [115]. Interest and Income - Interest expense decreased due to refinancing in February 2025, while interest income increased due to a rise in average cash and cash equivalents [102][103]. - Grant income for the three months ended December 31, 2025, increased by approximately $0.4 million compared to the prior year period, primarily related to ongoing studies [104]. - The company anticipates a significant increase in research and development expenses as it continues clinical trials and develops its product pipeline [90].